2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
29
Stomach Neoplasms
25
Rectal Neoplasms
25
Colonic Neoplasms
13
Neoplasms
3
Neoplasm Metastasis
3
Adenocarcinoma
3
Gastrointestinal Neoplasms
2
Waldenstrom Macroglobulinemia
1
Turcot syndrome
1
Recurrence
1
Rcctal Cancer
1
Peripheral Nervous System Diseases
1
Metastatic HER2 Positive Gastroesophageal Junction Cancer
1
Locally Advanced Rectal Cancer (LARC)
1
Locally Advanced Rectal Cancer
1
Locally Advanced Gastric Cancer
1
Locally Advanced Colorectal Cancer
1
Intestinal Neoplasms
1
HER2-positive Locally Advanced Resectable Gastric Cancer
1
HER2-positive Colorectal Cancer
1
Gastrointestinal Diseases
1
Gastric Cancer Stage
1
Gastric Adenocarcinoma
1
Esophageal Neoplasms
1
Digestive System Diseases
1
Colorectal Cancer Metastatic
1
Colonic Diseases
1
Carcinoma
1
Adenocarcinoma of the Lower Rectum
1
Interventions
Cyclophosphamide
153
Dexamethasone
141
Rituximab
85
fludarabine
79
Lenalidomide
72
Cytarabine
70
Bortezomib
64
fludarabine phosphate
63
Gemcitabine
62
venetoclax
54
Etoposide
53
pomalidomide
52
pembrolizumab
52
Paclitaxel
48
Cisplatin
48
Carboplatin
48
Peripheral Blood Stem Cell Transplantation
47
Filgrastim
40
Radiotherapy
39
Busulfan
37
Calcium Dobesilate
36
Methotrexate
34
Melphalan
34
Bevacizumab
33
carfilzomib
32
Cyclosporine
32
Azacitidine
32
Mycophenolic Acid
30
Vincristine
29
Bendamustine Hydrochloride
29
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
XELOX
×
Clear all
NCT06475352
2026-04-23
FUDOSE
UNICANCER
Phase 2
Recruiting
400 enrolled